Ivacaftor
1. Cystic Fibrosis Foundation Patient Registry. 2009 Annual Data Report to the
Center Directors. Bethesda, Maryland. 2010 Cystic Fibrosis Foundation.
2. Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cystic
Fibrosis 2008;7(5):450-453.
3. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis
gene: cloning and characterization of complementary DNA. Science 1989, Sep
8; 245(4922):1066-73.
4. Ferkol T, Rosenfeld M, and Milla C. Cystic Fibrosis Pulmonary Exacerbations. J
Pediatr 2006; 148:259-64.
5. Konstan MW, Berger M. Current Understanding of the inflammatory process in
cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997; 11:481-2.
6. Flume PA et al. Cystic Fibrosis Pulmonary Guidelines: chronic medications for
maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957-69.
7. Davis PB, Drumm M, and Konstan MW. Cystic Fibrosis. Am J Respir Crit Care 
Med 1996; 154:1229-1256.
8. Illek B, et al. Defective function of the cystic fibrosis-causing mis-sense mutation
G551D is recovered by genistein. Am J Physiol 1999; 277: C833-9.
9. Corey M, et al. Longitudinal Analysis of Pulmonary Function Decline in Patients
with Cystic Fibrosis. J Pediatr 1997; 131:809-14.
10. Quittner, AL, et al. Determination of the Minimal Clinically Important Difference
Scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom
Scale in Two Populations of Patients with Cystic Fibrosis and Chronic
Pseudomonas aeruginosa Airway Infection. Chest 2009; 135 (6): 1610-18.
11. Miller MR, et al. Standardisation of Spirometry. Eur Respir J 2005; 26:319-38.
12. Konstan, MW, et al. Growth and Nutritional Indexes in Early Life are Predictive
of Pulmonary Function in CF. J Pediatr 2003; 142:624-30.
13. Beker, LT, et al. Stature as a Prognostic Factor in Cystic Fibrosis Survival. J Am 
Diet Assoc, 2001; 4:438-42.
14. Doring G, et al. Antibiotic Therapy against Pseudomonas aeruginosa in cystic
fibrosis: a European Consensus. Eur Respir J 2000; 16: 749-67.
15. Fuchs HJ, et al. Effect of Aerosolized Recombinant Human DNase on
Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients
with Cystic Fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331
(10):637-42.
